Barriers to antipsychotic discontinuation in nursing homes: An exploratory study

Aging and Mental Health

Volumn 18, Issue 3, 2014, Pages 346-353

  Azermai, Majda ^a   Vander Stichele, Robert R H ^a   Van Bortel, Luc M ^a   Elseviers, Monique M ^a,b  

^a GHENT UNIVERSITY   (Belgium)

^b UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Institutional care (nursing homes etc.); Pharmacological treatment; Psychological and behavioral symptoms

Indexed keywords

NEUROLEPTIC AGENT;

AGED; ARTICLE; BELGIUM; CLINICAL PRACTICE; DECISION MAKING; FEMALE; HEALTH CARE SURVEY; HUMAN; MALE; MIDDLE AGED; NURSING HOME; NURSING PRACTICE; TREATMENT WITHDRAWAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BELGIUM; DECISION MAKING; FEMALE; HEALTH CARE SURVEYS; HUMANS; MALE; MIDDLE AGED; NURSE'S PRACTICE PATTERNS; NURSING HOMES; PHYSICIAN'S PRACTICE PATTERNS; WITHHOLDING TREATMENT;

EID: 84894871808     PISSN: 13607863     EISSN: 13646915     Source Type: Journal    
DOI: 10.1080/13607863.2013.832732     Document Type: Article

References (27)

1. Azermai, M., Elseviers, M., Petrovic, M., van Bortel, L., & Vander Stichele, R.H. (2011). Assessment of antipsychotic prescribing in Belgian nursing homes. International Psychogeriatric, 23, 1240-1248.
2. Azermai, M., Petrovic, M., Elseviers, M.M., Bourgeois, J., Van Bortel, L.M., & Vander Stichele, R.H. (2012). Systematic appraisal of dementia guidelines for the management of behavioural and psychological symptoms. Ageing Research Reviews, 11(1), 78-86.
3. Azermai, M., Petrovic, M., Engelborghs, S., Elseviers, M.M., Van der Mussele, S., Debruyne, H., . . . Vander Stichele, R. H. (2013). The effects of abrupt antipsychotic discontinuation in cognitively impaired older persons: A pilot study. Aging & Mental Health, 17(1), 125-132.
4. Ballard, C., Creese, B., Corbett, A., & Aarsland, D. (2011). Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. Expert Opinion on Drug Safety, 10, 35-43.
5. Ballard, C., Lana, M.M., Theodoulou, M., Douglas, S., McShane, R., Jacoby, R., . . . Juszczak, E. (2008). A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial). PLoS Medicine, 5, e76.
6. Banerjee S. (2009). The use of antipsychotic medication for people with dementia: Time for action. A report for the Minister of State for Care Services, Department of Health.
7. Briesacher, B.A., Limcangco, M.R., Simoni-Wastila, L., Doshi, J.A., Levens, S.R., Shea, D.G., & Stuart B. (2005). The quality of antipsychotic drug prescribing in nursing homes. Archives of Internal Medicine, 165, 1280-1285.
8. Bronskill, S.E., Anderson, G.M., Sykora, K., Wodchis, W.P., Gill, S., Shulman, K.I., & Rochon P.A. (2004). Neuroleptic drug therapy in older adults newly admitted to nursing homes: Incidence, dose, and specialist contact. Journal of the American Geriatrics Society, 52, 749-755.
9. Brookmeyer, R., Johnson, E., Ziegler-Graham, K., & Arrighi, H.M. (2007). Forecasting the global burden of Alzheimer's disease. Alzheimer's & Dementia, 3, 186-191.
10. Burke, A.D., & Tariot, P.N. (2009). Atypical antipsychotics in the elderly: A review of therapeutic trends and clinical outcomes. Expert Opinion on Pharmacotherapy, 10, 2407-2414.
11. Cody, M., Beck, C., & Svarstad, B.L. (2002). Challenges to the use of nonpharmacologic interventions in nursing homes. Psychiatric Services, 53, 1402-1406.
12. Cohen-Mansfield, J., Lipson, S., Werner, P., Billig, N., Taylor, L., & Woosley, R. (1999). Withdrawal of haloperidol, thioridazine, and lorazepam in the nursing home: A controlled, double-blind study. Archives of Internal Medicine, 159, 1733-1740.
13. Cornege-Blokland, E., Kleijer, B.C., Hertogh, C.M., & van Marum, R.J. (2012). Reasons to prescribe antipsychotics for the behavioral symptoms of dementia: A survey in Dutch nursing homes among physicians, nurses, and family caregivers. Journal of the American Medical Directors Association, 13, 80-86.
14. Declercq, T., Petrovic, M., Azermai, M., Van der Stichele, R., De Sutter, A.I., van Driel, M.L., & Christiaens, T. (2013). Withdrawal versus continuation of antipsychotics for behavioural and psychological symptoms in older people with dementia. Cochrane Database of Systematic Reviews, 3, CD007726. doi:10.1002/14651858.CD007726.pub2
15. Devanand, D.P., & Schultz, S.K. (2011). Consequences of antipsychotic medications for the dementia patient. American Journal of Psychiatry, 168(8), 767-769.
16. European Medicine Agency (EMA). (2004). Public statement on the safety of Olanzapine. Retrieved from http://www.bfarm. de/SharedDocs/1-Downloads/DE/ Pharmakovigilanz/amsicher- akt/emea-zyprexa-st.pdf?-blob = publicationFile
17. Katz, S., & Akpom, C.A. (1976). A measure of primary sociobiological functions. International Journal of Health Services, 6, 493-508.
18. Lyketsos, C.G., Lopez, O., Jones, B., Fitzpatrick, A.L., Breitner, J., & DeKosky, S. (2002). Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: Results from the cardiovascular health study. Journal of the American Medical Association, 288, 1475-1483.
19. Medicines and Healthcare Products Regulatory Agency (MHRA). (2008). Conventional typical antipsychotics: Increased mortality in dementia. Retrieved from http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087985
20. Medicines and Healthcare products Regulatory Agency (MHRA). (2009). Antipsychotics: Use in elderly people with dementia. Retrieved from http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON088116
21. Powell, R., & Single, H. (1996). Methodology matters - V: Focus groups. International Journal for Quality in Health Care, 8(5), 499-504.
22. Reisberg, B., Borenstein, J., Salob, S.P., Ferris, S.H., Franssen, E., & Georgotas, A. (1987). Behavioral symptoms in Alzheimer's disease: Phenomenology and treatment. Journal of Clinical Psychiatry, 48 (Suppl), 9-15.
23. Ruths, S., Straand, J., Nygaard, H.A., & Aarsland, D. (2008). Stopping antipsychotic drug therapy in demented nursing home patients: A randomized, placebo-controlled study - the Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 23, 889-895.
24. Schneider, L.S., Dagerman, K.S., & Insel, P. (2005). Risk of death with atypical antipsychotic drug treatment for dementia: Meta-analysis of randomized placebo-controlled trials. Journal of the American Medical Association, 294, 1934-1943.
25. Sterke C.S., van Beeck E.F., van der Velde N., Ziere G., Petrovic M., Looman C.W., & van der Cammen T.J. (2012). New insights: Dose-response relationship between psychotropic drugs and falls: A study in nursing home residents with dementia. Journal of Clinical Pharmacology, 52(6), 947-955.
26. US Food and Drug Administration (FDA). (2005). Public health advisory: Deaths with antipsychotics in elderly patients with behavioral disturbances. Retrieved from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationfor PatientsandProviders/ DrugSafetyInformationforHeathcare Professionals/PublicHealthAdvisories/UCM053171
27. US Food and Drug Administration (FDA). (2008). Antipsychotics are not indicated for the treatment of dementia-related psychosis. Retrieved from http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ucm124830.htm